Table 2.
Adhesion GPCRs associated to kidney disease.
| aGPCR member | References | Nephroseq (x-fold) | FireBrowse (x-fold) | NCIGDC | cBio | ||
|---|---|---|---|---|---|---|---|
| ccRCC | chRCC | pRCC | |||||
| Adgrl1 | - | mDN (1.596) | 0.420 | 1.870 | 0.919 | - | - |
| Adgrl2 | - | IgA (1.734), DN (1.791), LN (2.228) CKD (2.204) | 1.060 | 0.867 | 0.766 | - | - |
| Adgrl3 | - | - | 0.590 | 0.124 | 0.076 | - | - |
| Adgrl4 | Nie et al., 2012 | IgA (2.757), LN (2.493), mDN (1.525) | 2.130 | 0.405 | 0.179 | - | chRCC (11%) |
| Adgre1 | - | DN (1.566), mDN (1.654), mLN (3.238) | 7.740 | 1.95 | 3.210 | - | - |
| Adgre2 | - | V (1.718), LN (1.756) | 5.750 | 1.110 | 2.270 | - | - |
| Adgre3 | - | CKD (5.716) | 1.920 | 0.518 | 2.510 | - | - |
| Adgre4 | - | CKD (6.363) | - | - | - | - | - |
| Adgre5 | - | IgA (2.243), DN (2.488), V (2.278) HT (2.132), FSGS (2.121) MCD (1.642), LN (2.264) MG (1.645) | 2.550 | 0.336 | 1.960 | - | - |
| Adgra1 | - | CKD (5.460), mDN (3.564) | 0.081 | 1.390 | 0.138 | - | - |
| Adgra2 | - | APOL1 (1.526) | 2.920 | 0.754 | 0.219 | - | - |
| Adgra3 | - | CKD (2.253), APOL1 (1.905) | 0.857 | 0.476 | 1.840 | - | chRCC (15%) |
| Adgrc1 | - | - | 1.090 | 0.176 | 0.871 | ccRCC (11%) pRCC (10%) | ccRCC (15%) |
| Adgrc2 | - | - | 0.577 | 0.199 | 0.709 | - | - |
| Adgrc3 | - | - | 2.190 | 3.060 | 4.770 | ccRCC (12%) pRCC (10%) | chRCC (15%) |
| Adgrd1 | - | mDN (1.630) | 0.288 | 0.073 | 0.325 | - | - |
| Adgrd2 | - | CKD (2.294) | 1.220 | - | 1.870 | - | - |
| Adgrf1 | - | mDN (2.708), CKD (5.413) | 0.002 | 0.544 | 0.146 | - | - |
| Adgrf2 | - | CKD (6.115) | 0.966 | 0.084 | 2.560 | - | - |
| Adgrf3 | - | - | 0.050 | 0.160 | 0.099 | - | - |
| Adgrf4 | - | CKD (5.402) | 2.150 | 0.118 | 3.310 | - | chRCC (11%) |
| Adgrf5 | Nie et al., 2012 | - | 0.702 | 1.600 | 0.056 | - | - |
| Adgrb1 | Calderón-Zamora et al., 2017; Mathema and Na-Bangchang, 2017 | - | 0.910 | 0.010 | 1.040 | - | chRCC (11%) |
| Adgrb2 | - | CKD (1.786) | 0.424 | 0.355 | 2.110 | - | chRCC (14%) |
| Adgrb3 | - | CKD (3.092) | 0.169 | 0.052 | 0.240 | - | - |
| Adgrg1 | - | FSGS (3.100), CKD (2.189), mDN (2.145) | 0.703 | 3.890 | 0.476 | - | - |
| Adgrg2 | Kudo et al., 2007 | DN (1.701), CKD (4.762), mDN (2.221), mLN (2.832) | 2.340 | 1.180 | 0.413 | - | chRCC (11%) |
| Adgrg3 | Wang et al., 2013 | mDN (2.938) | 2.230 | 3.890 | 1.610 | - | - |
| Adgrg4 | - | CKD (4.004) | 1.160 | 0.539 | 1.490 | - | - |
| Adgrg5 | - | CKD (1.605) | 2.410 | 0.941 | 2.100 | - | - |
| Adgrg6 | - | DN (1.942), CKD (3.872), mLN (1.700) | 1.900 | 0.418 | 2.00 | - | - |
| Adgrg7 | - | CKD (5.656) | 1.990 | 2.080 | 1.970 | - | - |
| Adgrv1 | - | CKD (6.362) | 0.072 | 0.399 | 0.028 | ccRCC (16%) pRCC (19%) | chRCC (11%) |
APOL1, APOL1-associated kidney disease; ccRCC, clear cell renal cell carcinoma; chRCC, chromophobe renal cell carcinoma; CKD, chronic kidney disease; DN, diabetic nephropathy; FSGS, focal segmental glomerulosclerosis; HT, hypertension-injured kidney; IgA, IgA nephropathy; LN, lupus nephritis; MCD, minimal change disease; mDN, mouse model of diabetic nephropathy; MG, membranous glomerulopathy; mLN, mouse Berthier model of lupus nephritis with proteinuria; pRCC, papillary renal cell carcinoma; V, vasculitis-injured kidney; red boxes, <2.5-fold downregulation; green boxes, >2.5-fold upregulation.